Company Overview

Universal Ibogaine Inc. is a Canada-based life sciences company focused on addiction treatment services and research centered on ibogaine and related psychedelic-assisted therapies. The company operates in the healthcare services and mental health and addiction treatment industries, with an emphasis on medically supervised interventions for substance use disorders, including opioid and alcohol dependence. Its activities primarily involve operating treatment clinics and advancing clinical and regulatory understanding of ibogaine-based therapies.

The company’s primary revenue drivers have historically been patient treatment services delivered through affiliated or controlled clinics rather than pharmaceutical product sales. Universal Ibogaine Inc. was incorporated in Canada and became publicly listed on the TSX Venture Exchange under the ticker IBO.V. Its evolution reflects broader interest in alternative and psychedelic-assisted treatments for addiction, although ibogaine remains a controlled or restricted substance in several jurisdictions, shaping the company’s operational and geographic strategy.

Business Operations

The core business of Universal Ibogaine Inc. centers on its addiction treatment services segment, which involves operating or supporting clinics that provide medically supervised ibogaine and addiction recovery programs. These services typically combine medical screening, monitored administration, and post-treatment integration support. Revenue generation has been primarily service-based, dependent on patient volumes and clinic utilization rather than insurance reimbursement.

Operations are conducted through subsidiaries and affiliated entities, most notably Clear Sky Recovery, which has been publicly identified as a key operating clinic brand. The company does not publicly disclose large-scale proprietary technology assets, and its value proposition relies more on clinical protocols, operational expertise, and regulatory navigation than on patented compounds. Information on material joint ventures or long-term strategic partnerships beyond clinic-level arrangements is limited, and some operational details are not fully disclosed in public filings.

Strategic Position & Investments

Strategically, Universal Ibogaine Inc. has positioned itself as an early mover in the regulated delivery of ibogaine-based addiction treatments, focusing on jurisdictions where such services can be legally provided. Growth initiatives have included expanding clinic capacity, improving medical oversight standards, and increasing brand recognition within the addiction treatment market.

The company has announced investments related to clinic operations and, at various times, explored research or data collection initiatives to support broader acceptance of ibogaine therapies. Public disclosures do not consistently identify large acquisitions or a diversified portfolio of subsidiaries beyond Clear Sky Recovery, and information regarding emerging technologies or formal pharmaceutical development remains limited. Data inconclusive based on available public sources regarding advanced-stage clinical trials or regulatory submissions for ibogaine as a drug product.

Geographic Footprint

Universal Ibogaine Inc. is headquartered in Canada, with operational focus extending into Mexico, where ibogaine treatment services have historically been more feasible under local regulatory frameworks. The company’s market presence has primarily been concentrated in North America, serving international clients who travel for treatment rather than operating a wide network of global facilities.

Beyond Canada and Mexico, there is no verified evidence of sustained operations or investments across Europe, Asia, or other continents. International influence appears to be limited to patient outreach and brand visibility rather than physical infrastructure or regulatory engagement in multiple jurisdictions.

Leadership & Governance

Leadership of Universal Ibogaine Inc. includes executives with backgrounds in healthcare operations, public company management, and addiction treatment services. The company has been founder-led in its earlier stages, with governance structured around a board typical of TSX Venture Exchange issuers. Strategic vision communicated in public disclosures emphasizes patient safety, medical oversight, and cautious engagement with regulatory environments.

Key executives disclosed in public filings include:

• Nick Karos – Chief Executive Officer
• Jim Pettit – Chief Financial Officer
• Dave Rivas – President

The leadership philosophy, as reflected in company communications, centers on operational discipline and positioning the company within evolving regulatory and clinical standards for addiction treatment, though detailed long-term governance or succession plans are not extensively described in publicly available documents.